Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease
Nature Medicine2017Vol. 23(5), pp. 579–589
Citations Over TimeTop 1% of 2017 papers
Oxford IBD Cohort Investigators, Nathaniel R. West, Ahmed N. Hegazy, Benjamin M. J. Owens, Samuel J. Bullers, Bryan Linggi, Sofia Buonocore, Margherita Coccia, Dieter Görtz, Sébastien This, Felix Stockenhuber, Johanna Pott, Matthias Friedrich, Grigory Ryzhakov, Frédéric Baribaud, Carrie Brodmerkel, Constanze Cieluch, Nahid Rahman, Gerhard Müller‐Newen, Raymond J. Owens, Anja A. Kühl, Kevin J. Maloy, Scott E. Plevy, Satish Keshav, Simon Travis, Fiona Powrie
Related Papers
- → The synovial expression and serum levels of interleukin‐6, interleukin‐11, leukemia inhibitory factor, and oncostatin m in rheumatoid arthritis(1997)235 cited
- → Circulating IL‐6‐type cytokines and sIL‐6R in patients with multiple myeloma(1999)49 cited
- Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus.(1997)
- → Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis(2000)10 cited
- → Measurement of Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-11 Levels in Serum, Saliva, and Gingival Crevicular Fluid of Patients with Periodontal Diseases(2021)2 cited